HRP20080027T3 - 4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid - Google Patents

4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid

Info

Publication number: HRP20080027T3
Authority: HR; Croatia
Prior art keywords: morpholin; piperidine; methoxy; amide; hydroxy
Prior art date: 2004-05-24

Application number

HR20080027T

Other languages

English (en)

Croatian (hr)

Inventor

Flohr Alexander

Moreau Jean-Luc

Maria Poli Sonia

Riemer Claus

Steward Lucinda

Original Assignee

F. Hoffmann - La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-24

Filing date

2005-05-17

Publication date

2008-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34967309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20080027(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-05-17 Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag

2008-05-31 Publication of HRP20080027T3 publication Critical patent/HRP20080027T3/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

HR20080027T 2004-05-24 2005-05-17 4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid HRP20080027T3 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04102262		2004-05-24
PCT/EP2005/005329 WO2005116026A1 (en)	2004-05-24	2005-05-17	4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Publications (1)

Publication Number	Publication Date
HRP20080027T3 true HRP20080027T3 (hr)	2008-05-31

Family

ID=34967309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20080027T HRP20080027T3 (hr)	2004-05-24	2005-05-17	4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid

Country Status (38)

Country	Link
US (1)	US7368446B2 (es)
EP (1)	EP1753760B1 (es)
JP (1)	JP4668265B2 (es)
CN (1)	CN1956983B (es)
AR (1)	AR048973A1 (es)
AT (1)	ATE382619T1 (es)
AU (1)	AU2005247567B2 (es)
BR (1)	BRPI0511543B1 (es)
CA (1)	CA2567703C (es)
CR (1)	CR8703A (es)
CY (1)	CY1108104T1 (es)
DE (1)	DE602005004142T2 (es)
DK (1)	DK1753760T3 (es)
DO (1)	DOP2005000091A (es)
EA (1)	EA011279B1 (es)
EC (1)	ECSP067018A (es)
ES (1)	ES2297710T3 (es)
GT (1)	GT200500124A (es)
HN (1)	HN2005000238A (es)
HR (1)	HRP20080027T3 (es)
IL (1)	IL179364A (es)
MA (1)	MA28601B1 (es)
MX (1)	MXPA06013417A (es)
MY (1)	MY140011A (es)
NO (1)	NO336939B1 (es)
NZ (1)	NZ550763A (es)
PA (1)	PA8633901A1 (es)
PE (1)	PE20060274A1 (es)
PL (1)	PL1753760T3 (es)
PT (1)	PT1753760E (es)
RS (1)	RS50574B (es)
SI (1)	SI1753760T1 (es)
SV (1)	SV2006002125A (es)
TN (1)	TNSN06371A1 (es)
TW (1)	TWI358297B (es)
UA (1)	UA87142C2 (es)
WO (1)	WO2005116026A1 (es)
ZA (1)	ZA200609136B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE521512C2 (sv) *	2001-06-25	2003-11-11	Niconovum Ab	Anordning för administrering av en substans till främre delen av en individs munhåla
CA2511185C (en)	2002-12-20	2012-09-18	Niconovum Ab	A physically and chemically stable nicotine-containing particulate material
WO2007104573A2 (en)	2006-03-16	2007-09-20	Niconovum Ab	Improved snuff composition
MX2010000938A (es) *	2007-07-23	2010-07-01	Synosia Therapeutics Inc	Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
AU2010204118B2 (en)	2009-01-12	2012-12-20	Icagen, Inc.	Sulfonamide derivatives
US8168785B2 (en) *	2009-06-17	2012-05-01	Biotie Therapies, Inc.	Benzothiazole derivatives
WO2011101861A1 (en)	2010-01-29	2011-08-25	Msn Laboratories Limited	Process for preparation of dpp-iv inhibitors
CA2804173C (en)	2010-07-09	2015-01-13	Pfizer Limited	Sulfonamide nav1.7 inhibitors
WO2012060844A1 (en) *	2010-11-05	2012-05-10	Biotie Therapies, Inc	A2a antagonists as cognition and motor function enhancers
ES2627541T3 (es) *	2012-04-20	2017-07-28	Ucb Pharma, S.A.	Métodos para tratar la enfermedad de Parkinson
CA2988918A1 (en)	2015-06-19	2016-12-22	Biotie Therapies, Inc.	Controlled-release tozadenant formulations
WO2018059531A1 (zh) *	2016-09-30	2018-04-05	苏州晶云药物科技有限公司	一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
CA3073343A1 (en) *	2017-08-21	2019-02-28	Merck Patent Gmbh	Quinoxaline derivatives as adenosine receptor antagonists
IL272637B2 (en)	2017-08-21	2024-03-01	Merck Patent Gmbh	History of benzaimidazole, their preparation and medicines containing them
WO2019141096A1 (zh) *	2018-01-19	2019-07-25	四川科伦博泰生物医药股份有限公司	取代脲类化合物及其制备方法和用途
AU2019405950A1 (en)	2018-12-20	2021-07-15	Biotie Therapies, Inc.	Methods for treating cancer using tozadenant
DE102019110904B4 (de)	2019-04-26	2022-01-20	Helmholtz-Zentrum Dresden - Rossendorf E. V.	N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
CN116407539B (zh) *	2021-12-30	2025-01-10	上海现代药物制剂工程研究中心有限公司	依匹哌唑甲基脂肪酸酯的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH505543A (de)	1968-11-01	1971-04-15	Ciba Geigy Ag	Schädlingsbekämpfungsmittel
LU63457A1 (es)	1970-07-06	1971-11-12
US4028374A (en)	1975-11-03	1977-06-07	Morton-Norwich Products, Inc.	Antibacterial thiocyanatobenzothiazoles
DE2656468A1 (de)	1976-12-14	1978-06-15	Boehringer Mannheim Gmbh	N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
KR930005004B1 (ko)	1985-04-15	1993-06-11	쟈안센 파아마슈우티카 엔. 부이.	치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
FI91859C (fi)	1987-06-17	1994-08-25	Eisai Co Ltd	Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en)	1988-05-24	1989-12-15	Pfizer	Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
WO1990015801A1 (en)	1989-06-22	1990-12-27	Pfizer Inc.	Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
ATE103589T1 (de)	1989-11-10	1994-04-15	Agrolinz Agrarchemikalien	Verfahren zur herstellung reiner, unsymmetrisch disubstituierter harnstoffe.
US5376665A (en)	1992-05-21	1994-12-27	Otsuka Pharmaceutical Factory, Inc.	Phosphonic diester derivatives
FR2753970B1 (fr)	1996-10-01	1998-10-30	Synthelabo	Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
JPH11130761A (ja)	1997-10-24	1999-05-18	Otsuka Pharmaceut Co Ltd	ベンゾチアゾール誘導体
DE69833224T2 (de)	1997-11-10	2006-09-28	Bristol-Myers Squibb Co.	Benzothiazole als protein tyrosin-kinase inhibitoren
CN1288462A (zh)	1998-01-23	2001-03-21	法玛西雅厄普约翰美国公司	噁唑烷酮组合库、组合物和制备方法
WO2000018767A2 (en)	1998-09-30	2000-04-06	Neurogen Corporation	2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
GB9824579D0 (en)	1998-11-10	1999-01-06	Novartis Ag	Organic compounds
UA71587C2 (uk)	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів
IL133680A0 (en)	1999-09-10	2001-04-30	Can Fite Technologies Ltd	Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
EP1280739B1 (en)	2000-05-12	2005-11-09	Corning Incorporated	Method for manufacturing an optical fiber preform with a protective coating
YU96502A (sh) *	2000-06-21	2006-01-16	F. Hoffmann-La Roche Ag.	Derivati benzotiazola
US6727247B2 (en) *	2001-12-10	2004-04-27	Hoffman-La Roche Inc.	Substituted benzothiazole amide derivatives
US6713499B2 (en) *	2001-12-12	2004-03-30	Hoffman-La Roche Inc.	7-Amino-benzothiazole derivatives

2005
- 2005-05-17 NZ NZ550763A patent/NZ550763A/en not_active IP Right Cessation
- 2005-05-17 UA UAA200613530A patent/UA87142C2/ru unknown
- 2005-05-17 RS RSP-2008/0125A patent/RS50574B/sr unknown
- 2005-05-17 SI SI200530160T patent/SI1753760T1/sl unknown
- 2005-05-17 AU AU2005247567A patent/AU2005247567B2/en not_active Expired
- 2005-05-17 EP EP05741185A patent/EP1753760B1/en not_active Expired - Lifetime
- 2005-05-17 PT PT05741185T patent/PT1753760E/pt unknown
- 2005-05-17 EA EA200602048A patent/EA011279B1/ru not_active IP Right Cessation
- 2005-05-17 AT AT05741185T patent/ATE382619T1/de active
- 2005-05-17 DE DE602005004142T patent/DE602005004142T2/de not_active Expired - Lifetime
- 2005-05-17 MX MXPA06013417A patent/MXPA06013417A/es active IP Right Grant
- 2005-05-17 JP JP2007513750A patent/JP4668265B2/ja not_active Expired - Fee Related
- 2005-05-17 BR BRPI0511543-4A patent/BRPI0511543B1/pt not_active IP Right Cessation
- 2005-05-17 HR HR20080027T patent/HRP20080027T3/xx unknown
- 2005-05-17 DK DK05741185T patent/DK1753760T3/da active
- 2005-05-17 CA CA2567703A patent/CA2567703C/en not_active Expired - Lifetime
- 2005-05-17 PL PL05741185T patent/PL1753760T3/pl unknown
- 2005-05-17 WO PCT/EP2005/005329 patent/WO2005116026A1/en not_active Ceased
- 2005-05-17 ES ES05741185T patent/ES2297710T3/es not_active Expired - Lifetime
- 2005-05-17 CN CN200580016875XA patent/CN1956983B/zh not_active Expired - Fee Related
- 2005-05-18 US US11/132,019 patent/US7368446B2/en not_active Expired - Lifetime
- 2005-05-20 MY MYPI20052309A patent/MY140011A/en unknown
- 2005-05-20 DO DO2005000091A patent/DOP2005000091A/es unknown
- 2005-05-20 TW TW094116495A patent/TWI358297B/zh not_active IP Right Cessation
- 2005-05-23 GT GT200500124A patent/GT200500124A/es unknown
- 2005-05-23 HN HN2005000238A patent/HN2005000238A/es unknown
- 2005-05-23 PE PE2005000569A patent/PE20060274A1/es active IP Right Grant
- 2005-05-23 PA PA20058633901A patent/PA8633901A1/es unknown
- 2005-05-23 AR ARP050102104A patent/AR048973A1/es not_active Application Discontinuation
- 2005-05-24 SV SV2005002125A patent/SV2006002125A/es unknown
2006
- 2006-10-24 CR CR8703A patent/CR8703A/es unknown
- 2006-11-02 ZA ZA200609136A patent/ZA200609136B/xx unknown
- 2006-11-14 TN TNP2006000371A patent/TNSN06371A1/fr unknown
- 2006-11-16 IL IL179364A patent/IL179364A/en active IP Right Grant
- 2006-11-21 EC EC2006007018A patent/ECSP067018A/es unknown
- 2006-11-22 MA MA29481A patent/MA28601B1/fr unknown
- 2006-12-12 NO NO20065732A patent/NO336939B1/no not_active IP Right Cessation
2008
- 2008-02-28 CY CY20081100232T patent/CY1108104T1/el unknown

Also Published As

Publication number	Publication date
PL1753760T3 (pl)	2008-06-30
TWI358297B (en)	2012-02-21
SV2006002125A (es)	2006-02-15
CA2567703A1 (en)	2005-12-08
ATE382619T1 (de)	2008-01-15
BRPI0511543B1 (pt)	2022-05-10
DE602005004142D1 (de)	2008-02-14
NO20065732L (no)	2006-12-22
EP1753760B1 (en)	2008-01-02
BRPI0511543A (pt)	2008-01-02
MA28601B1 (fr)	2007-05-02
PE20060274A1 (es)	2006-04-14
RS50574B (sr)	2010-05-07
DK1753760T3 (da)	2008-04-14
SI1753760T1 (sl)	2008-04-30
EA011279B1 (ru)	2009-02-27
HK1105199A1 (en)	2008-02-06
MXPA06013417A (es)	2007-01-23
IL179364A0 (en)	2007-03-08
JP4668265B2 (ja)	2011-04-13
CR8703A (es)	2007-10-04
ZA200609136B (en)	2008-07-30
JP2008500295A (ja)	2008-01-10
EP1753760A1 (en)	2007-02-21
GT200500124A (es)	2005-12-26
AU2005247567A1 (en)	2005-12-08
TNSN06371A1 (fr)	2008-02-22
US20050261289A1 (en)	2005-11-24
NZ550763A (en)	2010-07-30
CN1956983A (zh)	2007-05-02
DE602005004142T2 (de)	2009-01-02
WO2005116026A1 (en)	2005-12-08
DOP2005000091A (es)	2005-06-29
PT1753760E (pt)	2008-02-12
ES2297710T3 (es)	2008-05-01
PA8633901A1 (es)	2006-05-16
MY140011A (en)	2009-11-30
UA87142C2 (en)	2009-06-25
IL179364A (en)	2013-01-31
CN1956983B (zh)	2010-05-26
CY1108104T1 (el)	2014-02-12
EA200602048A1 (ru)	2007-06-29
HN2005000238A (es)	2008-07-14
AU2005247567B2 (en)	2010-09-02
AR048973A1 (es)	2006-06-14
TW200612937A (en)	2006-05-01
NO336939B1 (no)	2015-11-30
US7368446B2 (en)	2008-05-06
CA2567703C (en)	2013-03-05
ECSP067018A (es)	2006-12-29

Publication	Publication Date	Title
HRP20080027T3 (hr)	2008-05-31	4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid
EA200500238A1 (ru)	2005-10-27	Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
NO20064077L (no)	2006-11-10	Kemokinreseptorantagonister
HRP20120323T1 (en)	2012-05-31	Diarylhydantoin compounds
WO2005110410A3 (en)	2007-03-29	Kinase inhibitors as therapeutic agents
DK1585739T3 (da)	2011-06-20	Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
DE602004008098D1 (de)	2007-09-20	Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
WO2006049835A3 (en)	2007-11-22	Indole and benzimidazole derivatives
WO2005074603A3 (en)	2006-11-09	Aminobenzoxazoles as therapeutic agents
NO20082389L (no)	2008-08-18	2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
EA200801381A1 (ru)	2009-02-27	Производные пиримидина
WO2009065919A3 (de)	2009-10-01	Organische verbindungen
NO20070122L (no)	2007-03-01	Quinazolinonderivater anvendelige som vanilloidantagonister
WO2005103037A3 (de)	2006-01-12	Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
MY150661A (en)	2014-02-14	Pyridin-3-yl derivatives as immunomodulating agents
WO2009065920A3 (de)	2009-10-15	Verbindungen
NO20092286L (no)	2009-08-13	Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
EA200500239A1 (ru)	2005-12-29	Новый способ синтеза (1s)-4-,5-диметокси-1-(метиламинометил)-бензоциклобутана и его солей присоединения и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
MXPA02003977A (es)	2003-09-25	Inhibidores de adhesion de celula mediada por al°2.
AU2008255733A8 (en)	2013-06-13	Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
SE0400284D0 (sv)	2004-02-10	Novel compounds
MXPA05012463A (es)	2006-01-30	Combinaciones farmaceuticas de un inhibidor de bomba protonica y un compuesto que modifica la motilidad gastrointestinal.
MX2010003849A (es)	2010-04-27	Antagonistas de cgrp.
DK1753723T3 (da)	2008-10-20	Substituerede quinolinderivater som mitotiske kinesininhibitorer
EP1314712A4 (en)	2004-12-15	NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT